EGFR and non-small cell lung carcinoma: In the ongoing phase III KEYNOTE-042 trial of patients with treatment-naïve, advanced, EGFR/ALK WT NSCLC and at least 1% tumor PD-L1 expression, there was no statistically significant PFS benefit among patients receiving Pembrolizumab compared with those receiving chemotherapy, except for those with the highest level of PD-L1 expression [44].